Diamedica Therapeutics (DMAC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Matthew Caufield’s rating is based on the promising potential of Diamedica Therapeutics’ DM199 as a novel treatment for preeclampsia, a condition currently lacking FDA-approved therapies. The enthusiasm from key opinion leaders (KOLs) for DM199’s ability to improve placental perfusion, reduce blood pressure, and enhance endothelial function underscores its potential as a disease-modifying therapy. The upcoming Phase 2 proof-of-concept topline results, expected between June and July 2025, are crucial in demonstrating DM199’s efficacy and safety, particularly its ability to lower systolic blood pressure and not cross the placental barrier.
Furthermore, the initial Phase 2 data will assess DM199’s impact on maternal systolic blood pressure and uterine artery blood flow, leveraging its mechanism as a recombinant human tissue kallikrein-1 enzyme. This mechanism is anticipated to increase placental perfusion and improve endothelial health while reducing elevated blood pressure. The combination of these factors supports the Buy rating as the company approaches significant clinical milestones.
According to TipRanks, Caufield is an analyst with an average return of -14.4% and a 33.14% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Unity Biotechnology, and Immunic.